EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024

POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA Results from a large population-based study show reassuring data, with no increased risk of #CVD, #VTE or certain cancers compared to TNFi or IL-17i @SteZhao @RheumNow #EULAR2024

1200 PsA pts 6 countries IL17is as effective as TNFi and JAK despite more failed bDMARDs and monotherapy & faster onset action than IL23s ⁦@RheumNow⁩ #EULAR2024 https://t.co/SM5CA7KUvd

• https://twitter.com/drpnash/status/1801879213739237768/photo/1

#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B

• https://twitter.com/Yuz6Yusof/status/1801876904506478640/photo/1
• https://twitter.com/Yuz6Yusof/status/1801876904506478640/photo/1

Cohort from Netherlands 400+ PsA pts IR first bioDMARD 300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi 3year retention rates 12 mo 75% cyclers 80% swappers 24mo 60% cyclers 56% swappers No difference in treatment failure or DAS28 CRP #EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG

• https://twitter.com/AurelieRheumo/status/1801520487605911565/photo/1

EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS - smells tastes & looks like a Tyk2 - acne signal? @rheumnow #EULAR2024

FAPI PET/CT entheseal & synovial fibroblast activation predicts PsA in high risk PsO better than MUS @RheumNow #EULAR2024 https://t.co/uqmEvMg9WN

• https://twitter.com/drpnash/status/1801473801806319804/photo/1

more evidence in PsA - switch MOA rather than cycle within class failed first TNF @RheumNow #EULAR2024 https://t.co/hf2UB5MXEy

• https://twitter.com/drpnash/status/1801508656623526235/photo/1

opposing point of view especially in males at 3 years !@RheumNow #EULAR2024 https://t.co/CXxIScQbFD

• https://twitter.com/drpnash/status/1801509729711136816/photo/1

New #JAKi #disease #results #Baricitinib in #alopecia #areata esp 4mg/d #Upadacitinib in Crohn’s #Upa in #polyarticular #JIA & kid #PsA +RCT of UPA in #GCA Awaiting results of #SLE With #deucravicitinib & UPA #RCTs #EULAR2024 @eular_org @RheumNow

Do we give enough attention to pts mental health? 2 cohort 400+ RA tREACH & DEPAR 500+ PsA RA 20% depression 30% anxiety PsA 19% depression 22% anxiety 2 yrs no remission RA OR 2.5 depression OR 1.7 anxiety PsA OR 6.10 depression OR 4.67 anxiety @RheumNow #EULAR2024 POS0946 https://t.co/ok4HRNJqgY

• https://twitter.com/AurelieRheumo/status/1801624630626484634/photo/1

Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A

• https://twitter.com/i/web/status/1801590870908518546
• https://twitter.com/synovialjoints/status/1801590870908518546/photo/1

What is better in #PsA #psoriatic #arthritis #TNFi or #apremilast #PDE4i #COREVITAS database study in #PsA YOU can guess the answer! 1st line advanced RxTNFi lasts longer - retention Vs PDE4i #EULAR2024 @RheumNow @eular_org POS0990 https://t.co/VmYG6Rj87c

• https://twitter.com/Janetbirdope/status/1801585969130356929/photo/1